Although there are still challenges in the management of patients with systemic juvenile idiopathic arthritis (sJIA), there have been overall improvements, according to a German study.  The researchers sited the introduction of treatment guidelines and their implementation in routine care, the early involvement of experienced multidisciplinary teams, and the trend toward earlier and faster step-up treatment regimens with conventional disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs as reasons for the more favorable prognoses seen with sJIA.